Loading...

Novo Nordisk A/S

NVONYSE
Healthcare
Drug Manufacturers - General
$70.30
$5.38(8.29%)

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/S’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 84.0/100

Key Financials

Market Cap298.7B
P/E Ratio17.98
EPS (TTM)$3.69
ROE0.81%
Fundamental Analysis

AI Price Forecasts

1 Week$74.81
1 Month$73.11
3 Months$61.42
1 Year Target$118.71

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 35.62, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $118.71.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.98 and a market capitalization of 298.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;